Cognitive Impairment Associated With Schizophrenia (CIAS) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000

Cognitive Impairment Associated with Schizophrenia (CIAS) pipeline market research report provides comprehensive information on the therapeutics under development for Cognitive Impairment Associated with Schizophrenia (CIAS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cognitive Impairment Associated with Schizophrenia (CIAS) and features dormant and discontinued projects.

What are the key targets in the CIAS pipeline market?

The key targets in the CIAS pipeline market are Glutamate Ionotropic Receptor NMDA Type Subunit, Neuronal Acetylcholine Receptor Subunit Alpha 7, Potassium Voltage Gated Channel Subfamily C Member 1, Cholinergic Receptor Muscarinic, Sodium and Chloride Dependent Glycine Transporter 1, 5-Hydroxytryptamine Receptor 4, 5-Hydroxytryptamine Receptor 5A, Catechol O Methyltransferase, D Amino Acid Oxidase, and Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA. Glutamate Ionotropic Receptor NMDA Type Subunit has the highest number of pipeline products.

CIAS pipeline market, by target

CIAS pipeline market, by target

For more target insights, download a free report sample

What are the key MoA in the CIAS pipeline market?

The key MoA in the CIAS pipeline market are Neuronal Acetylcholine Receptor Subunit Alpha 7 Agonist, Potassium Voltage Gated Channel Subfamily C Member 1 Activator, Sodium And Chloride Dependent Glycine Transporter 1 Inhibitor, 5-Hydroxytryptamine Receptor 4 Agonist, 5-Hydroxytryptamine Receptor 5A Antagonist, Catechol O Methyltransferase Inhibitor, Cholinergic Receptor Muscarinic Agonist, D Amino Acid Oxidase Inhibitor, Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABAAntagonist, and Gamma-Aminobutyric Acid Type B Receptor Subunit (Gamma Aminobutyric Acid Agonist. Neuronal Acetylcholine Receptor Subunit Alpha 7 Agonist has the highest number of pipeline products in the CIAS pipeline market.

CIAS pipeline market, by MoA

CIAS pipeline market, by MoA

For more MoA insights, download a free report sample

What are the key RoA in the CIAS pipeline market?

The key RoA in the CIAS pipeline market are Oral and Nasal. Oral has the highest number of pipeline products in the the CIAS pipeline market.

CIAS pipeline market, by RoA

CIAS pipeline market, by RoA

For more RoA insights, download a free report sample

What are the key molecule type in the CIAS pipeline market?

The key molecule type in the CIAS pipeline market are Small Molecule and Synthetic Peptide. Small molecule has the highest number of pipeline products in the CIAS market.

CIAS pipeline market, by molecule type

CIAS pipeline market, by molecule type

For more molecule type insights, download a free report sample

What are the key companies in the CIAS pipeline market?

The key companies in the CIAS pipeline market are Autifony Therapeutics Ltd, Boehringer Ingelheim International GmbH, Neurocrine Biosciences Inc, Novartis AG, Suven Life Sciences Ltd, Accure Therapeutics SL, Anvyl LLC, Astellas Pharma Inc, AstraZeneca Plc, and Atai Life Sciences NV. Autifony Therapeutics Ltd has the highest number of pipeline products in the CIAS pipeline market.

CIAS pipeline market, by companies

CIAS pipeline market, by companies

To know more about companies, download a free report sample

Market report overview

Key targets Glutamate Ionotropic Receptor NMDA Type Subunit, Neuronal Acetylcholine Receptor Subunit Alpha 7, Potassium Voltage Gated Channel Subfamily C Member 1, Cholinergic Receptor Muscarinic, Sodium And Chloride Dependent Glycine Transporter 1, 5-Hydroxytryptamine Receptor 4, 5-Hydroxytryptamine Receptor 5A, Catechol O Methyltransferase, D Amino Acid Oxidase, and Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA
Key MoA Neuronal Acetylcholine Receptor Subunit Alpha 7 Agonist, Potassium Voltage Gated Channel Subfamily C Member 1 Activator, Sodium And Chloride Dependent Glycine Transporter 1 Inhibitor, 5-Hydroxytryptamine Receptor 4 Agonist, 5-Hydroxytryptamine Receptor 5A Antagonist, Catechol O Methyltransferase Inhibitor, Cholinergic Receptor Muscarinic Agonist, D Amino Acid Oxidase Inhibitor, Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABAAntagonist, and Gamma-Aminobutyric Acid Type B Receptor Subunit (Gamma Aminobutyric Acid Agonist
Key RoA Oral and Nasal
Key Molecule Type Small Molecule and Synthetic Peptide
Key companies Autifony Therapeutics Ltd, Boehringer Ingelheim International GmbH, Neurocrine Biosciences Inc, Novartis AG, Suven Life Sciences Ltd, Accure Therapeutics SL, Anvyl LLC, Astellas Pharma Inc, AstraZeneca Plc, and Atai Life Sciences NV

 Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cognitive Impairment Associated with Schizophrenia (CIAS) (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Cognitive Impairment Associated with Schizophrenia (CIAS) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cognitive Impairment Associated with Schizophrenia (CIAS) (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cognitive Impairment Associated with Schizophrenia (CIAS) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cognitive Impairment Associated with Schizophrenia (CIAS) (Central Nervous System)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cognitive Impairment Associated with Schizophrenia (CIAS) (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cognitive Impairment Associated with Schizophrenia (CIAS) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Accure Therapeutics SL
Astellas Pharma Inc
AstraZeneca Plc
Atai Life Sciences NV
Autifony Therapeutics Ltd
Biogen Inc
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Coronis NeuroSciences Ltd
Cyclerion Therapeutics Inc
EuMentis Therapeutics Inc
F. Hoffmann-La Roche Ltd
Merck & Co Inc
Monument Therapeutics Ltd
Neurocrine Biosciences Inc
Novartis AG
Pfizer Inc
SK Biopharmaceuticals Co Ltd
Spherium Biomed SL
Suven Life Sciences Ltd
Vanda Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Cognitive Impairment Associated With Schizophrenia (CIAS) – Overview

Cognitive Impairment Associated With Schizophrenia (CIAS) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Cognitive Impairment Associated With Schizophrenia (CIAS) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cognitive Impairment Associated With Schizophrenia (CIAS) – Companies Involved in Therapeutics Development

Accure Therapeutics SL

Astellas Pharma Inc

AstraZeneca Plc

Atai Life Sciences NV

Autifony Therapeutics Ltd

Biogen Inc

Boehringer Ingelheim International GmbH

Bristol-Myers Squibb Co

Coronis NeuroSciences Ltd

Cyclerion Therapeutics Inc

EuMentis Therapeutics Inc

F. Hoffmann-La Roche Ltd

Merck & Co Inc

Monument Therapeutics Ltd

Neurocrine Biosciences Inc

Novartis AG

Pfizer Inc

SK Biopharmaceuticals Co Ltd

Spherium Biomed SL

Suven Life Sciences Ltd

Vanda Pharmaceuticals Inc

Cognitive Impairment Associated With Schizophrenia (CIAS) – Drug Profiles

ACT-02 – Drug Profile

Product Description

Mechanism Of Action

History of Events

ASP-5736 – Drug Profile

Product Description

Mechanism Of Action

AUT-1 – Drug Profile

Product Description

Mechanism Of Action

History of Events

AUT-6 – Drug Profile

Product Description

Mechanism Of Action

History of Events

AUT-9 – Drug Profile

Product Description

Mechanism Of Action

History of Events

AVL-3288 – Drug Profile

Product Description

Mechanism Of Action

basmisanil – Drug Profile

Product Description

Mechanism Of Action

History of Events

BI-425809 – Drug Profile

Product Description

Mechanism Of Action

History of Events

BI-474121 – Drug Profile

Product Description

Mechanism Of Action

History of Events

BMS-955829 – Drug Profile

Product Description

Mechanism Of Action

CAD-8688 – Drug Profile

Product Description

Mechanism Of Action

History of Events

CAD-9303 – Drug Profile

Product Description

Mechanism Of Action

History of Events

CP-102 – Drug Profile

Product Description

Mechanism Of Action

History of Events

CY-6463 – Drug Profile

Product Description

Mechanism Of Action

History of Events

EM-036 – Drug Profile

Product Description

Mechanism Of Action

luvadaxistat – Drug Profile

Product Description

Mechanism Of Action

History of Events

MK-4334 – Drug Profile

Product Description

Mechanism Of Action

NBI-1065846 – Drug Profile

Product Description

Mechanism Of Action

History of Events

pesampator – Drug Profile

Product Description

Mechanism Of Action

History of Events

PF-03463275 – Drug Profile

Product Description

Mechanism Of Action

RL-007 – Drug Profile

Product Description

Mechanism Of Action

History of Events

samelisant – Drug Profile

Product Description

Mechanism Of Action

History of Events

SKL-20540 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule for Cognitive Impairment Associated With Schizophrenia – Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit COMT for Cognitive Impairment Associated with Schizophrenia (CIAS) and Unspecified Psychiatric Disorders – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Modulate CHRM for Central Nervous System and Respiratory Disorders – Drug Profile

Product Description

Mechanism Of Action

SP-14040 – Drug Profile

Product Description

Mechanism Of Action

SUVND-4010 – Drug Profile

Product Description

Mechanism Of Action

VQW-765 – Drug Profile

Product Description

Mechanism Of Action

History of Events

VU-0467154 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Cognitive Impairment Associated With Schizophrenia (CIAS) – Dormant Projects

Cognitive Impairment Associated With Schizophrenia (CIAS) – Discontinued Products

Cognitive Impairment Associated With Schizophrenia (CIAS) – Product Development Milestones

Featured News & Press Releases

Dec 14, 2021: atai Life Sciences announces successful outcome of phase 2a biomarker trial of RL-007 in cognitive impairment associated with schizophrenia

May 27, 2021: Cyclerion Therapeutics announces publication of CY6463 preclinical data in frontiers in pharmacology

May 24, 2021: Boehringer Ingelheim’s investigational treatment for Cognitive Impairment Associated with Schizophrenia receives FDA Breakthrough Therapy Designation

Apr 27, 2021: Cyclerion Therapeutics hosted webinar to discuss pipeline progress, provides update on CY6463 clinical program

Apr 20, 2021: Cyclerion Therapeutics to host pipeline update webinar

Mar 02, 2021: Neurocrine Biosciences announces top-line results from phase II interact study evaluating Luvadaxistat (NBI-1065844) for the treatment of negative symptoms and cognitive impairment associated with Schizophrenia (CIAS)

Feb 01, 2015: ASCIL Biopharm cooperates in a Project awarded with a “RETOS-Colaboración” grant

Jan 27, 2015: Spark, a new public-private project created to develop a drug to fight the cognitive impairment associated with schizophrenia

Apr 17, 2013: SK Biopharma Announces FDA’s Authorization Of IND For SKL15508 For Treatment Of Cognitive Impairment Associated With Schizophrenia

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Accure Therapeutics SL, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Astellas Pharma Inc, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by AstraZeneca Plc, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Atai Life Sciences NV, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Autifony Therapeutics Ltd, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Biogen Inc, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Boehringer Ingelheim International GmbH, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Bristol-Myers Squibb Co, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Coronis NeuroSciences Ltd, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Cyclerion Therapeutics Inc, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by EuMentis Therapeutics Inc, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by F. Hoffmann-La Roche Ltd, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Merck & Co Inc, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Monument Therapeutics Ltd, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Neurocrine Biosciences Inc, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Novartis AG, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Pfizer Inc, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by SK Biopharmaceuticals Co Ltd, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Spherium Biomed SL, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Suven Life Sciences Ltd, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Vanda Pharmaceuticals Inc, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) – Dormant Projects, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) – Dormant Projects, 2022 (Contd..1)

Cognitive Impairment Associated With Schizophrenia (CIAS) – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS), 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

  • What are the key targets in the CIAS pipeline market?

    The key targets in the CIAS pipeline market are Glutamate Ionotropic Receptor NMDA Type Subunit, Neuronal Acetylcholine Receptor Subunit Alpha 7, Potassium Voltage Gated Channel Subfamily C Member 1, Cholinergic Receptor Muscarinic, Sodium And Chloride Dependent Glycine Transporter 1, 5-Hydroxytryptamine Receptor 4, 5-Hydroxytryptamine Receptor 5A, Catechol O Methyltransferase, D Amino Acid Oxidase, and Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA.

  • What are the key MoA in the CIAS pipeline market?

    The key MoA in the CIAS pipeline market are Neuronal Acetylcholine Receptor Subunit Alpha 7 Agonist, Potassium Voltage Gated Channel Subfamily C Member 1 Activator, Sodium And Chloride Dependent Glycine Transporter 1 Inhibitor, 5-Hydroxytryptamine Receptor 4 Agonist, 5-Hydroxytryptamine Receptor 5A Antagonist, Catechol O Methyltransferase Inhibitor, Cholinergic Receptor Muscarinic Agonist, D Amino Acid Oxidase Inhibitor, Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABAAntagonist, and Gamma-Aminobutyric Acid Type B Receptor Subunit (Gamma Aminobutyric Acid Agonist.

  • What are the key RoA in the CIAS pipeline market?

    The key RoA in the CIAS pipeline market are Oral and Nasal.

  • What are the key molecule type in the CIAS pipeline market?

    The key molecule type in the CIAS pipeline market are Small Molecule and Synthetic Peptide. Small molecule has the highest number of pipeline products in the CIAS market.

  • What are the key companies in the CIAS pipeline market?

    The key companies in the CIAS pipeline market are Autifony Therapeutics Ltd, Boehringer Ingelheim International GmbH, Neurocrine Biosciences Inc, Novartis AG, Suven Life Sciences Ltd, Accure Therapeutics SL, Anvyl LLC, Astellas Pharma Inc, AstraZeneca Plc, and Atai Life Sciences NV.

Cognitive Impairment Associated With Schizophrenia (CIAS) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Cognitive Impairment Associated With Schizophrenia (CIAS) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Cognitive Impairment Associated With Schizophrenia (CIAS) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.